Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of BenevolentAI.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
BenevolentAI
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
4-8 Maple Street, London, W1T 5HD
Telephone
Telephone
+44 (0)2037 819 360

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Uner the collaboration, Merck will leverage BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in oncology, neurology and immunology. BenevolentAI will identify innovative compounds through Hit Identification to pre-clinical stage.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck Group

Deal Size: $594.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration September 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BEN-8744 is a peripherally restricted small molecule and derived from the Benevolent PlatformTM and is a potential first-in-class PDE10 inhibitor for the treatment of Ulcerative Colitis.


Lead Product(s): BEN-8744

Therapeutic Area: Gastroenterology Product Name: BEN-8744

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies for amyotrophic lateral sclerosis.


Lead Product(s): BEN-34712

Therapeutic Area: Neurology Product Name: BEN-34712

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: The Sheffield Institute for Translational Neuroscience

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BEN-2293 is a selective inhibitor of the three tropomyosin-related kinases (Trk) receptors (TrkA, TrkB and TrkC) formulated to be administered topically in patients with mild-to-moderate AD.


Lead Product(s): BEN2293

Therapeutic Area: Dermatology Product Name: BEN2293

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BEN-8744 is an orally administered, peripherally restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis and with the potential for other indications within inflammatory bowel disease.


Lead Product(s): BEN-8744

Therapeutic Area: Gastroenterology Product Name: BEN-8744

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 21, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This is the third novel target from the collaboration that has been identified using the Benevolent Platform™ across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca.


Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Undisclosed

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The innovative collaboration structure scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform™ — an AI-driven drug discovery platform and biomedical knowledge graph with AstraZeneca’s scientific expertise and rich datasets.


Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Undisclosed

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BEN-2293 is a selective Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis.


Lead Product(s): BEN-2293

Therapeutic Area: Dermatology Product Name: BEN-2293

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 11, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AI-generated target was identified through Benevolent Platform® and AstraZeneca's scientific expertise and rich datasets. The Benevolent Platform® predicted this novel target, which was subsequently biologically validated through AstraZeneca's rigorous experimental testing.


Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Undisclosed

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The randomised control trial included more than 1,000 patients and began on May 8 to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir in hospitalised patients with COVID-19.


Lead Product(s): Baricitinib

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY